Nama's AI scorecard currently rates Palvella Therapeutics Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does PVLA report earnings?

Palvella Therapeutics's next scheduled report is on Mar 31, 2027. Analysts expect EPS of -$2.04.

What is the PVLA price target?

The median analyst price target from 15 analysts is $232.00, with a range of $205.00 – $267.00.

Is PVLA Shariah compliant?

Nama's AAOIFI-style screen reads Palvella Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Palvella Therapeutics (PVLA)

Healthcare · Biotechnology · NASDAQ

Palvella Therapeutics (PVLA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.53B and a free-cash-flow yield of -1.3%. Nama's AI scorecard rates it Sell, 3.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 3.5/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +66.1% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-49.7%

How far the last close sits under the highest price of the past five years.

Market cap	$2.53B
Trailing P/E	—
Price / book	11.7
Price / sales	—
FCF yield	-1.3%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	—
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

PVLA earnings

Next report: Mar 31, 2027 (Q4 2026, EPS estimate -$2.04). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$1.70	-$1.73	+1.7%	—
Q2 2026	Aug 4, 2026	-$1.52	-$1.15	-32.2%	$0
Q1 2026	May 7, 2026	-$1.20	-$0.93	-29.0%	$0
Q4 2025	Mar 31, 2026	-$1.08	-$0.91	-18.7%	$0

PVLA analyst price target

Median target $232.00 from 15 analysts, ranging $205.00 – $267.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live PVLA data on Nama Insights →

PVLA FAQ

Is PVLA a buy?: Nama's AI scorecard currently rates Palvella Therapeutics Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does PVLA report earnings?: Palvella Therapeutics's next scheduled report is on Mar 31, 2027. Analysts expect EPS of -$2.04.
What is the PVLA price target?: The median analyst price target from 15 analysts is $232.00, with a range of $205.00 – $267.00.
Is PVLA Shariah compliant?: Nama's AAOIFI-style screen reads Palvella Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.